Regresar

Evaluation of CIMAvaxEGF for the treatment of lung cancer: Meta-analysis of controlled clinical trials

Abstract:

CIMAvaxEGF is a therapeutic cancer vaccine developed in Cuba and fully licensed in the country for use in adult patients with lung cancer non-small cell (NSCLC) in stage IIIB/IV. The aims The objective of this work is to determine the effectiveness of the CIMAvaxEGF vaccine through the combined meta-analysis technique. A PubMed search of "CIMAvaxEGF", "vaccine", 20 articles were published by Cuban authors between January 1, 1995 and September 30, 2015, describing the results of the clinical studies performed. During the development of CIMAvaxEGF, mainly those published by Cuban researchers in refereed international scientific journals. Twelve articles describe clinical trials in Cuba from 1995-2015 with CIMAvaxEGF; five Phase I with 135 patients, Phase II with 80 patients, two Phase III with 520 patients, 513 patients with Stage IV, an observational study with 378 patients and two studies sponsored by the investigator with 35 patients. These studies were selected by the Jadad scale the three controlled trials. The meta-analysis consisted of the construction of graph Forest Plot, sensitivity analysis and analysis accumulated. The meta-analysis shows favorable results to CIMAvaxEGF vaccine, with moderate heterogeneity (59.4%). The sensitivity analysis reveals that the test differs from most others is the EC056 Phase II. The cumulative analysis indicates that the result is known after the second trials.